Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Ann Surg Oncol. 2024 Sep;31(9):5594-5603. doi: 10.1245/s10434-024-15404-8. Epub 2024 May 10.
The prognostic impact of positive peritoneal lavage cytology (CY+) in patients with perihilar cholangiocarcinoma (PHC) remains unclear. The present study investigated the clinical significance of primary tumor resection of CY+ PHC.
We retrospectively evaluated 282 patients who underwent surgery for PHC between September 2002 and March 2022. The patients' clinicopathological characteristics and survival outcomes were compared between the CY negative (CY-) resected (n = 262), CY+ resected (n = 12), and CY+ unresected (n = 8) groups. Univariate and multivariate analyses were performed to identify prognostic factors for overall survival.
The expected residual liver volume was significantly higher in the CY+ resected group (61%) than in the CY- resected (47%) and CY+ unresected (37%) groups (p = 0.004 and 0.007, respectively). The CY+ resected group had a higher administration rate of postoperative therapy than the CY- resected group (58% vs. 16%, p = 0.002). Overall survival of the CY+ resected group was similar to that of the CY- resected group (median survival time [MST] 44.5 vs. 44.6, p = 0.404) and was significantly better than that of the CY+ unresected group (MST 44.5 vs. 17.1, p = 0.006). CY positivity was not a prognostic factor according to a multivariate analysis in patients with primary tumor resection.
The CY+ resected group showed better survival than the CY+ unresected group and a similar survival to that of the CY- resected group. Resection of the primary tumor with CY+ PHC may improve the prognosis in selected patients.
阳性腹膜灌洗细胞学(CY+)在肝门部胆管癌(PHC)患者中的预后影响尚不清楚。本研究探讨了 CY+PHC 患者行原发肿瘤切除的临床意义。
我们回顾性评估了 2002 年 9 月至 2022 年 3 月期间接受 PHC 手术的 282 例患者。比较了 CY-切除(n=262)、CY+切除(n=12)和 CY+未切除(n=8)组患者的临床病理特征和生存结局。采用单因素和多因素分析确定总生存的预后因素。
CY+切除组的预期剩余肝体积(61%)明显高于 CY-切除组(47%)和 CY+未切除组(37%)(p=0.004 和 0.007)。CY+切除组术后治疗的给药率高于 CY-切除组(58% vs. 16%,p=0.002)。CY+切除组的总生存与 CY-切除组相似(中位生存时间[MST]44.5 与 44.6,p=0.404),明显优于 CY+未切除组(MST44.5 与 17.1,p=0.006)。根据多因素分析,CY 阳性不是肿瘤切除患者的预后因素。
CY+切除组的生存优于 CY+未切除组,与 CY-切除组的生存相似。在选择的患者中,切除 CY+PHC 的原发肿瘤可能改善预后。